RE: RE: RE: RE: Another reason for the PhaseIIIbI believe the FDA would want a bigger sample group study. But I am not sure i the comparison with Mitomycin C is necessary.
I have sent an email to Johnathan Neely, ENDO's Assiciate Director of Investor Relations asking specifically this. Hope he'll enlighten us.